Publications by authors named "K Unagami"
Background: Partial nephrectomy (PN) is strongly recommended as nephron-sparing surgery for T1 renal tumors. Although there have been some reports of robot-assisted PN (RAPN) for solitary allograft renal tumors, only a few cases of RAPN for multifocal allograft renal tumors have been reported. Herein, we report a case of a patient who underwent RAPN for multifocal allograft renal cell carcinoma (RCCs).
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on the impact of SARS-CoV-2 on kidney transplant (KTx) recipients, highlighting limited data on their treatment and prognosis during the pandemic.
- Out of 282 KTx patients infected with the virus, 6.7% experienced severe outcomes, with certain underlying health conditions increasing the risk of complications.
- Treatment strategies evolved over time in response to new variants, with antiviral drugs being administered as they gained approval.
Article Synopsis
- Solid organ transplant (SOT) recipients show poor antibody production against SARS-CoV-2 post-vaccination, raising concerns about their immune responses.
- A study involving 614 SOT recipients vaccinated with mRNA vaccines revealed an overall seropositivity rate of 43% one month after the second dose, increasing to 70% by six months.
- Kidney, lung, and simultaneous pancreas-kidney transplant recipients had lower antibody levels at 3 and 6 months compared to other organ types, indicating slower antibody acquisition relative to the general population.
Background: The number of marginal living kidney donors has increased. Medically complex donors who have hypertension, older age, or low estimated glomerular filtration rate (eGFR) have been more likely to be used.
Methods: We conducted a retrospective cohort study of living kidney donors at a single center.
Background: Letermovir is approved for cytomegalovirus (CMV) prophylaxis in adult allogeneic hematopoietic cell transplantation recipients worldwide and is also approved in the United States for CMV prophylaxis in adult high-risk (D+/R-) kidney transplant recipients (KTRs). The safety and efficacy of letermovir for CMV prophylaxis in adult Japanese KTRs are reported here.
Methods: In this Phase 3, single-arm, open-label study, adult Japanese KTRs with CMV serostatuses D+/R-, D+/R+, and D-/R+ received letermovir 480 mg daily orally within 7 days post-transplant through Week 28.